Pas­sage Bio CEO de­parts af­ter March lay­offs as biotech goes with le­gal chops for in­ter­im re­place­ment

Pas­sage Bio’s am­bi­tions will be han­dled by a new face go­ing for­ward as Bruce Gold­smith ex­it­ed Tues­day, adding to the list of biotechs fac­ing the un­re­lent­ing bear mar­ket that has forced lead­er­ship shuf­fles to hap­pen at break­neck speed.

The biotech said the May 31 sep­a­ra­tion was a “mu­tu­al agree­ment be­tween the Board and Dr. Gold­smith,” ac­cord­ing to an SEC fil­ing.

Gold­smith is leav­ing his CEO, pres­i­dent and board posts at the Jim Wil­son gene ther­a­py mak­er just months af­ter the biotech laid off 13% of its work­force. Al­so in March, R&D chief Eliseo Sali­nas quit as did board mem­ber Liam Rat­cliffe, who dis­agreed with the biotech’s “busi­ness plans and op­er­a­tions.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER